Table 2. Characteristics of the treatment responders and patients with stable disease.
| Patient ID | Disease stage | Age (years) | Prior therapies | Cytogenetic risk group | FLT3 ITD | NRAS | KRAS | No. of cycles | Response |
|---|---|---|---|---|---|---|---|---|---|
| 47# | Beyond first relapse | 53 | SCT, 7+3, HiDAC | Not available | wt | wt | wt | 8 | PR |
| 4 | Beyond first relapse | 68 | 7+3, tipifarnib, decitabine + vorinostat | Other | wt | wt | wt | 3 | MR (BM) |
| 5# | Beyond first relapse | 70 | Cytarabine, daunorubicin and oblimersen sodium, HiDAC, azacitidine + belinostat | Poor | wt | wt | wt | 3 | MR (PB) |
| 6 | Untreated AML (prior MDS) | 66 | Prior MDS treatment: azacitidine | Poor | wt | wt | wt | 2 | MR (PB) |
| 10# | Untreated AML (prior MDS) | 75 | Prior MDS treatment: Thalidomide + Dexamethasone, azacitidine, lenalidomide | Poor | wt | wt | MUT | 6 | uMR + HI-P |
| 8# | Beyond first relapse | 66 | 7+3, HiDAC, Gemtuzumab ozogamicin, zosuquidar | Other | wt | wt | wt | 2 | uMR |
| 27# | Untreated AML (prior MDS) | 70 | Prior MDS treatment: azacitidine, decitabine + valproic acid | Intermediate | wt | wt | wt | 2 | SD |
| 46# | First Relapse | 64 | Decitabine + vorinostat | Intermediate | wt | wt | wt | 4 | SD |
| 37 | Primary refractory | 62 | Decitabine + valproic acid | Poor | wt | wt | wt | 4 | SD |
| 28 | Primary refractory | 55 | 7+3, HiDAC, MEC, troxacitabine | Other | wt | wt | wt | 21 | SD |
#
Polymorphism for SNP rs3733542 in exon 18 of the KIT gene
SCT: stem cell transplant; 7+3: cytarabine/daunorubicin; HiDAC: high-dose cytarabine; wt: wild-type; PR: partial response; MR (BM): minor response (bone marrow); MR (PB): minor response (peripheral blood); AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MUT: mutated; uMR: unconfirmed minor response; HI-P: hematologic improvement-platelet; SD: stable disease; MEC: mitoxantrone/etoposide/cytarabine